Prognostic Value of Excision Repair Cross-complementing Gene 1 Expression for Cisplatin-Based Chemotherapy in Advanced Gastric Cancer

Abstract

<b>Background:</b> Association of excision repair cross-complementing gene 1 (ERCC1) expression and treatmentresponse and survival was evaluated in advanced stages of gastric cancer patients who were given differentplatinum-based chemotherapy. Patients and <br/><b>Methods</b>: Forty-one patients with advanced gastric cancer wereenrolled into the study from January 2000 to December 2009. ERCC1 expression was evaluated byimmunohistochemistry (IHC). <br/><b>Results</b>: Thirteen of the 41 patients (31%) were shown to have ERCC1 positivelesions. Although the clinical benefit from platin based chemotherapy was the same for ERCC1 positive andnegative patients, survival times were statistically significantly better in ERCC1 negative gastric cancer patients.<br/><b>Conclusion</b>: We suggest that IHC studies for ERCC1 may be useful in prediction of the clinical outcome ofadvanced gastric cancer patients treated with platin-based chemotherapy.